symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
ITOS,9.78,1.216372,435381,349946982,0,8.2-23.0,1.13,"iTeos Therapeutics, Inc.",USD,0001808865,US46565G1040,46565G104,NASDAQ Global Market,NASDAQ,Biotechnology,https://www.iteostherapeutics.com,"Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.",Dr. Michel  Detheux Ph.D.,Healthcare,US,125,339 217 0161,321 Arsenal Street,Cambridge,MA,02472-5710,,0,https://financialmodelingprep.com/image-stock/ITOS.png,2020-07-24,False,False,True,False,False
